Enhanced 𝝮3

Enhanced 𝝮3

60 Softgels
Regular price $40.00 Sale price$20.00 Save $20.00
/
  • In stock, ready to ship
  • Inventory on the way

IHN’s Enhanced 𝝮3 is a patented monoglyceride omega-3 fatty acid researched and developed in Canada. The innovative MaxSimil delivery system was shown to have superior absorption than the next leading brands of ethyl ester (EE) or reconstituted triglyceride (rTG) fish oil.

Omega-3 fatty acid has a long standing use as a food based therapy with cellular antioxidant and anti-inflammatory properties ,  Clinicians' expertise, evidence and patients' value are three key factors guiding evidence based selection of omega 3 fatty acid.



Medicinal Ingredients | 1 Softgel

Fish Oil 805 mg

Yielding:

EPA 320 mg

DHA 185 mg 

Non-Medicinal Ingredients: Capsule (bovine gelatin, glycerin, purified water), sunflower oil, lemon essential oil, natural mixed tocopherols

Recommended Dose:

Children 6 - 11 years: Two soft gels daily or as recommended by your health care practitioner.

Adolescents 12 - 17 years: Two soft gels daily or as recommended by your health care practitioner.

Adults 18 years and older: Two soft gels daily or as recommended by your health care practitioner.

Enhanced 𝝮3 with MaxSimil

Omega-3 fatty acid has a long standing use as a food based therapy with cellular antioxidant and anti-inflammatory properties ,  Clinicians' expertise, evidence and patients' value are three key factors guiding evidence based selection of omega 3 fatty acid. 

IHN’s Enhanced 𝝮3 fish oil is a patented monoglyceride omega-3 fatty acid researched and developed in Canada. The innovative Enhanced 𝝮3 delivery system was shown to have superior absorption than the next leading brands of ethyl ester (EE) or reconstituted triglyceride (rTG) fish oil.

Incomplete digestion leading to regurgitation is a common complaint for poor compliance of fish oil supplementation. Enhanced 𝝮3 was designed with clinicians and patients in mind; the natural emulsification of Enhanced 𝝮3 monoglyceride fish oil bypasses digestion and allows for quick uptake into the body. In fact, Enhanced 𝝮3 fish oil was shown to be absorbed even in the absence of digestive enzymes . A follow up second pharmacokinetic human study demonstrated that Enhanced 𝝮3 fish oils had two to three times greater absorption of EPA and DHA compared to leading brands of ethyl ester or reconstituted triglycerides. Meaning Enhanced 𝝮3 has the capacity to quickly achieve high omega 3 levels with lower daily servings.

How does MaxSimil work? 

MaxSimil is a patented delivery system developed by a Canadian professor that allows enhanced absorption of lipids into the body.  It does so by using the same natural digestive enzymes released by our body; MaxSimil enzymatic process transforms high EPA/DHA fish oils into a monoglyceride emulsion that can be directly absorbed into the intestinal cells, without the reliance on the first steps of digestion.

Enhanced 𝝮3 + MaxSimill omega 3 fatty acid has been evaluated in several phase 1 clinical trials demonstrating its superior absorption compared to ethyl ester (EE) or reconstituted triglyceride (rTG) fish oil . One trial with 14 participants examined benefits of MaxSimill DHA supplementation at correcting AA/DHA imbalance in cystic fibrosis patients. Compared to control (sunflower oil), MaxSimill delivering 4000 mg DHA was shown to be well absorbed in the absence of digestive enzymes Furthermore, MaxSimill was shown to exert anti-inflammatory benefits and correct erythrocyte arachidonic acid /docosahexaenoic acid ratio (AA/DHA) following one month daily supplementation

The two human pharmacokinetic studies demonstrated MaxSimil’s advanced absorption system is capable of bypassing digestion for rapid absorption and quickly raises blood plasma concentration of omega-3. The 2020 study by Brunet S, et al., with  twenty participants taking 3000 mg EPD+DHA of MaxSimil fish oil found that compared to control ethyl ester, MaxSimil omega 3 had 3.14 times greater peak plasma contraction in a 24hr period. 

The second study by Plourde M..,  (2021)  further concluded the superior bioavailability of MaxSimil. This time, MaxSimil was compared with reconstituted triglyceride (rTG) as control. MaxSimil had 2.1 times greater peak plasma contraction in a 24hr period.  In other words, 1 gram of MaxSimil fish oil will help you reach the same peak plasma contraction versus taking 3 grams of EE fish oil over 24 hours. In the case of rTG, 2 grams of fish oil is needed for every gram of MaxSimil fish oil to reach the same peak blood concentration. The findings from these studies are clinically consequential; The superior bioavailability of MaxSimil predigested monoglyceride means patients have the potential to achieve optimal omega-3 concentration at a lower serving.

Chronic medical conditions like obesity and hypertension are modifiable cardiometabolic risk factors highly predictive of hospitalization. Our HSP probiotics have been formulated to address the inflammatory biomarkers, hypercholesterolemia, and elevated BMI typically seen in people with reduced immune function. 

In a randomized double-blind placebo controlled trial with 32 overweight and obese women, our HSP strains were shown to be significantly correlated with healthy BMI, weight, fat mass, lean mass, conicity index, protein intake, monounsaturated fat intake, glycated hemoglobin,

TNF-α, and IL6/IL10. The bifidobacteria HSP strains have also demonstrated specific cholesterol absorption properties, leading to decreases in serum total cholesterol and LDL-C.

Enhanced 𝝮3 oils are sourced sustainably from non-GMO and antibiotic free small fish such as sardines and anchovies from South American waters. Furthermore the fish oil comes with several third party certifications including a five-star rating under the International Fish Oil Standards™ program (IFOS), sustainable fisheries certification by Friend of the Sea (FOS) and the Marine Stewardship Council (MSC) ensuring the highest purity.

Additional ongoing research evaluating MaxSimil

Vascepa is a pharmaceutical drug derived from fish oil. This omega 3- like pharmaceutical molecule is used as adjunct treatment alongside statin to reduce the risk of cardiovascular risk in adults with elevated triglycerides.  The early data from the clinical trial show that 2.0 g of MaxSimil EPA to be equivalent to 4.0g of Vascepa

Lactate threshold is a common blunder for professional athletes striving to achieve peak performance. Without adequate lactate clearance, it may contribute to poor exercise performance  A pilot study is evaluating if supplementation with MaxSimil omega-3 decreased the lactic acid concentration; early data suggest MaxSimil is able to decrease blood LA by 26% at maximum training . These early promising results provide additional therapeutic versatility for MaxSimil use in clinical practice.

 Calder, P. C. (2017). Omega-3 fatty acids and inflammatory processes: from molecules to man. Biochemical Society Transactions, 45(5), 1105–1115. https://doi.org/10.1042/bst20160474

 Anderson, E. J., Thayne, K. A., Harris, M., Shaikh, S. R., Darden, T. M., Lark, D. S., Williams, J. M., Chitwood, W. R., Kypson, A. P., & Rodriguez, E. (2014). Do Fish Oil Omega-3 Fatty Acids Enhance Antioxidant Capacity and Mitochondrial Fatty Acid Oxidation in Human Atrial Myocardium via PPARγ Activation? Antioxidants & Redox Signaling, 21(8), 1156–1163. https://doi.org/10.1089/ars.2014.5888

 Morin, C., Cantin, A., Vézina, F. A., & Fortin, S. (2018). The Efficacy of MAG-DHA for Correcting AA/DHA Imbalance of Cystic Fibrosis Patients. Marine Drugs, 16(6), 184. https://doi.org/10.3390/md16060184

 Chevalier, L., Plourde, M. Comparison of pharmacokinetics of omega-3 fatty acid supplements in monoacylglycerol or ethyl ester in humans: a randomized controlled trial. Eur J Clin Nutr (2020)

 Morin, C., Rodríguez, E., Blier, P., & Fortin, S. (2017). Potential Application of Eicosapentaenoic Acid Monoacylglyceride in the Management of Colorectal Cancer. Marine Drugs, 15(9), 283. https://doi.org/10.3390/md15090283

 Neptune Wellness Solution (n.d.). Marine Oils. Biodroga Nutraceuticals. Retrieved February 10, 2022, from https://www.biodrogasolutions.com/marine-oils

 Morin, C., Rousseau, R., & Fortin, S. (2013). Anti-proliferative effects of a new docosapentaenoic acid monoacylglyceride in colorectal carcinoma cells. Prostaglandins, Leukotrienes and Essential Fatty Acids, 89(4), 203–213. https://doi.org/10.1016/j.plefa.2013.07.004

 Morin, C., Blier, P. U., & Fortin, S. (2015). Eicosapentaenoic acid and docosapentaenoic acid monoglycerides are more potent than docosahexaenoic acid monoglyceride to resolve inflammation in a rheumatoid arthritis model. Arthritis Research & Therapy, 17(1). https://doi.org/10.1186/s13075-015-0653-y

 Morin, C., Fortin, S., Cantin, A. M., & Rousseau, R. (2011). Docosahexaenoic Acid Derivative Prevents Inflammation and Hyperreactivity in Lung. American Journal of Respiratory Cell and Molecular Biology, 45(2), 366–375. https://doi.org/10.1165/rcmb.2010-0156oc

 Morin, C., Cantin, A., Vézina, F. A., & Fortin, S. (2018). The Efficacy of MAG-DHA for Correcting AA/DHA Imbalance of Cystic Fibrosis Patients. Marine Drugs, 16(6), 184. https://doi.org/10.3390/md16060184

 Morin, C., Cantin, A., Vézina, F. A., & Fortin, S. (2018). The Efficacy of MAG-DHA for Correcting AA/DHA Imbalance of Cystic Fibrosis Patients. Marine Drugs, 16(6), 184. https://doi.org/10.3390/md16060184

 Antonutto G, Di Prampero PE. The concept of lactate threshold. A short review. J Sports Med Phys Fitness. 1995 Mar;35(1):6-12. PMID: 7474995.

 Fortin, S. (in press). mpact of Fish Oil Monoglycerides on the Modulation of Mitochondrial Functions and Lactate Threshold. NIH: ClinicalTrial.Gov.

 Cuenoud, B., Rochat, I., Gosoniu, M., Dupuis, L., Berk, E., Jaudszus, A., Mainz, J., Hafen, G., Beaumont, M., & Cruz-Hernandez, C. (2020). Monoacylglycerol form of omega-3s improves its bioavailability in humans compared to other forms. Nutrients, 12(4), 1014. https://doi.org/10.3390/nu12041014 

 Chevalier, L., & Plourde, M. (2020). Comparison of pharmacokinetics of omega-3 fatty acid supplements in monoacylglycerol or ethyl ester in humans: A randomized controlled trial. European Journal of Clinical Nutrition, 75(4), 680–688. https://doi.org/10.1038/s41430-020-00767-4 

 Stanton, A. V., James, K., Brennan, M. M., O’Donovan, F., Buskandar, F., Shortall, K., El-Sayed, T., Kennedy, J., Hayes, H., Fahey, A. G., Pender, N., Thom, S. A. M., Moran, N., Williams, D. J., & Dolan, E. (2020). Omega-3 index and blood pressure responses to eating foods naturally enriched with omega-3 polyunsaturated fatty acids: a randomized controlled trial. Scientific Reports, 10(1). https://doi.org/10.1038/s41598-020-71801-5

 Li, Z. H., Zhong, W. F., Liu, S., Kraus, V. B., Zhang, Y. J., Gao, X., Lv, Y. B., Shen, D., Zhang, X. R., Zhang, P. D., Huang, Q. M., Chen, Q., Wu, X. B., Shi, X. M., Wang, D., & Mao, C. (2020). Associations of habitual fish oil supplementation with cardiovascular outcomes and all cause mortality: evidence from a large population based cohort study. BMJ, m456. https://doi.org/10.1136/bmj.m456

 Balk EM, Adam GP, Langberg V, et al. Omega-3 Fatty Acids and Cardiovascular Disease: An Updated Systematic Review. Rockville (MD): Agency for Healthcare Research and Quality (US); 2016 Aug. (Evidence Reports/Technology Assessments, No. 223.) Available from: https://www.ncbi.nlm.nih.gov/books/NBK384547/

 Aung, T., Halsey, J., Kromhout, D., Gerstein, H. C., Marchioli, R., Tavazzi, L., Geleijnse, J. M., Rauch, B., Ness, A., Galan, P., Chew, E. Y., Bosch, J., Collins, R., Lewington, S., Armitage, J., & Clarke, R. (2018). Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks. JAMA Cardiology, 3(3), 225. https://doi.org/10.1001/jamacardio.2017.5205

 Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM; REDUCE-IT Investigators. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019 Jan 3;380(1):11-22. doi: 10.1056/NEJMoa1812792. Epub 2018 Nov 10. PMID: 30415628.

 Li, Z. H., Zhong, W. F., Liu, S., Kraus, V. B., Zhang, Y. J., Gao, X., Lv, Y. B., Shen, D., Zhang, X. R., Zhang, P. D., Huang, Q. M., Chen, Q., Wu, X. B., Shi, X. M., Wang, D., & Mao, C. (2020). Associations of habitual fish oil supplementation with cardiovascular outcomes and all cause mortality: evidence from a large population based cohort study. BMJ, m456. https://doi.org/10.1136/bmj.m456

 Bae, J. H., & Kim, G. (2018). Systematic review and meta-analysis of omega-3-fatty acids in elderly patients with depression. Nutrition Research, 50, 1–9. https://doi.org/10.1016/j.nutres.2017.10.013

 Liao, Y., Xie, B., Zhang, H., He, Q., Guo, L., Subramanieapillai, M., Fan, B., Lu, C., & McIntyre, R. S. (2019). Efficacy of omega-3 PUFAs in depression: A meta-analysis. Translational Psychiatry, 9(1). https://doi.org/10.1038/s41398-019-0515-5

 Bisgaard, H., Stokholm, J., Chawes, B. L., Vissing, N. H., Bjarnadóttir, E., Schoos, A. M. M., Wolsk, H. M., Pedersen, T. M., Vinding, R. K., Thorsteinsdóttir, S., Følsgaard, N. V., Fink, N. R., Thorsen, J., Pedersen, A. G., Waage, J., Rasmussen, M. A., Stark, K. D., Olsen, S. F., & Bønnelykke, K. (2016). Fish Oil–Derived Fatty Acids in Pregnancy and Wheeze and Asthma in Offspring. New England Journal of Medicine, 375(26), 2530–2539. https://doi.org/10.1056/nejmoa1503734

 Lin, J., Zhang, Y., Zhu, X., Wang, D., & Dai, J. (2018). Effects of supplementation with omega-3 fatty acids during pregnancy on asthma or wheeze of children: a systematic review and meta-analysis. The Journal of Maternal-Fetal & Neonatal Medicine, 33(10), 1792–1801. https://doi.org/10.1080/14767058.2018.1529161


Recently viewed